Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea · Delayed Price · Currency is KRW 17,990
-40 (-0.22%)
Sep 1, 2026, 3:30 PM KST
Onconic Therapeutics Revenue
Onconic Therapeutics had revenue of 24.40B KRW in the quarter ending June 30, 2026, with 158.68% growth. This brings the company's revenue in the last twelve months to 82.17B, up 179.26% year-over-year. In the year 2025, Onconic Therapeutics had annual revenue of 53.39B with 259.82% growth.
Revenue (ttm)
82.17B
Revenue Growth
+179.26%
P/S Ratio
9.94
Revenue / Employee
n/a
Employees
n/a
Market Cap
816.89B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.39B | 38.55B | 259.82% |
| Dec 31, 2024 | 14.84B | -6.22B | -29.53% |
| Dec 31, 2023 | 21.06B | 20.96B | 22,064.25% |
| Dec 31, 2022 | 95.00M | 35.00M | 58.33% |
| Dec 31, 2021 | 60.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Chabiotech | 1.31T |
| Medy-Tox | 251.08B |
| MEDIPOST | 74.84B |
| Komipharm International | 53.02B |
| Pharmicell | 23.94B |
| SillaJen | 10.92B |
| GI Innovation | 5.63B |